First-in-Human, Single-Ascending Dose and Food Effect Studies to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cetagliptin, a Dipeptidyl Peptidase-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

2021 ◽  
Author(s):  
Lu Wang ◽  
Jinmiao Lu ◽  
Sufeng Zhou ◽  
Yuqing Zhao ◽  
Lijun Xie ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Food Effect ◽  
Dipeptidyl Peptidase ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor

scholarly journals Effects of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin on Blood Pressure in Hypertensive Patients with Type 2 Diabetes Mellitus

2019 ◽  
Vol 32 (7) ◽  
pp. 695-702 ◽  
Author(s):  
Shinji Kishimoto ◽  
Yoshihiko Kinoshita ◽  
Takeshi Matsumoto ◽  
Tatsuya Maruhashi ◽  
Masato Kajikawa ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Dipeptidyl Peptidase ◽  
Hypertensive Patients ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor

scholarly journals Effects of the linagliptin, dipeptidyl peptidase-4 inhibitor, on bone fragility induced by type 2 diabetes mellitus in obese mice

2020 ◽  
Vol 14 (5) ◽  
pp. 218-225
Author(s):  
Junkichi Kanda ◽  
Megumi Furukawa ◽  
Nobuo Izumo ◽  
Taketoshi Shimakura ◽  
Noriaki Yamamoto ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Dipeptidyl Peptidase ◽  
Bone Fragility ◽  
Obese Mice ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor
Sign in / Sign up

Export Citation Format

Share Document